Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results